[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pharyngitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pharyngitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100651358","yanlishuang-buccal-dropping-pills-for-acute-pharyngitis-100651358",false,"NCT07761013","Yanlishuang Buccal Dropping Pills for Acute Pharyngitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of Miao Medicine Yanlishuang Buccal Dropping Pills in Adults With Acute Pharyngitis","YLS-AP-RCT","Inclusion Criteria:\n\n* Age 18 to 65 years, inclusive, of any sex.\n* Baseline throat-pain visual analog scale score of at least 4.\n* Meets the protocol-defined Western medicine diagnostic criteria for acute pharyngitis.\n* Acute onset with disease duration of 48 hours or less.\n* Provides written informed consent and is able to follow the study protocol.\n\nExclusion Criteria:\n\n* Prior use of Yanlishuang Buccal Dropping Pills before enrollment, or use before enrollment of any other Chinese or Western medicine for the target disease that, in the investigator's judgment, may affect efficacy evaluation.\n* Prodromal or accompanying throat symptoms of an acute infectious disease, such as measles, scarlet fever, or infectious mononucleosis; suppurative tonsillitis; peritonsillar abscess; retropharyngeal abscess; acute epiglottitis; or throat symptoms caused by another disease.\n* Modified Centor score of at least 2, with white blood cell count, absolute neutrophil count, and C-reactive protein all above the upper limit of normal, when the investigator considers bacterial infection or antibiotic treatment necessary.\n* Concurrent bacterial otitis media, sinusitis, laryngitis, bronchitis, pneumonia, acute nephritis, rheumatic fever, sepsis, or a similar complication.\n* Severe primary disease of the central nervous, hematopoietic, endocrine, cardiovascular\u002Fcerebrovascular, digestive, or other system, or a psychiatric disorder, that the investigator considers may affect participant safety or materially affect clinical evaluation.\n* Abnormal hepatic or renal function: alanine aminotransferase or aspartate aminotransferase greater than 1.5 times the upper limit of normal and\u002For serum creatinine above the upper limit of normal.\n* Suspected or confirmed history of alcohol or drug abuse.\n* Pregnancy, breastfeeding, preparation for pregnancy, or a recent childbearing plan.\n* Known allergy to any component of the study medication.\n* Participation in another clinical trial and use of an investigational product within the previous 1 month.\n* Constitutional spleen-stomach deficiency-cold or a condition considered unsuitable for study medication, including but not limited to acute or chronic gastritis, erosive gastritis, or gastroesophageal reflux disease.\n* Any other condition that the investigator considers makes the individual unsuitable for participation.","ALL","18 Years","65 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Acute pharyngitis commonly causes sore throat and pain on swallowing. This multicenter trial will compare Yanlishuang Buccal Dropping Pills with a matching placebo in 400 adults aged 18 to 65 years whose acute pharyngitis began within 48 hours and whose baseline throat-pain visual analog scale score is at least 4. Participants will be randomized 1:1 and treated under double-blind conditions. Each group will use four buccal dropping pills 4 to 6 times daily at intervals of at least 2 hours for up to 5 days. Participants whose sore throat resolves after at least 72 hours and remains absent for at least 24 hours may stop treatment early. The primary outcome is time to complete sore throat resolution. Secondary outcomes assess immediate pain relief, onset and resolution of pain, symptom and physical-sign response, complications, and work absence. Safety will be assessed using physical examinations, vital signs, laboratory tests, electrocardiograms, and adverse events.",[28],"Acute Pharyngitis",[30,31,32,33,34,35,36,37,38,39],"acute pharyngitis","sore throat","swallowing pain","resting throat pain","visual analog scale","Miao medicine","Traditional Chinese Medicine","Yanlishuang","buccal dropping pills","placebo-controlled trial","NOT_YET_RECRUITING","2026-08-07",{"date":43,"type":44},"2026-08-12","ACTUAL",{"date":46,"type":22},"2026-08-01",{"date":48,"type":22},"2027-06-29",{"name":50,"class":51},"Beijing University of Chinese Medicine","OTHER",10,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100636765","evaluation-of-treatments-for-sore-throat-associated-with-acute-pharyngitis-andor-viral-tonsillitis-100636765","NCT07569939","Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and\u002For Viral Tonsillitis","PharyTol","Inclusion Criteria:\n\n* Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment\n* Bacterial rhinopharyngitis with negative TROD test\n* Effective contraception for female patients of childbearing age\n* Cooperation and sufficient understanding to comply with the requirements of the trial\n* Acceptance of registration in the SI-RIPH database\n* Having received informed information and agreeing to give written consent\n* Affiliated with the French Social Security scheme.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fprevious allergy to any of the product components,\n* Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent otorhinolaryngology surgery (\\\u003C6 months),\n* Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),\n* Immunosuppression (according to patient's report),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","70 Years",{"count":62,"type":22},160,[25],"The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and\u002For viral-origin tonsillitis, while also assessing the benefit\u002Frisk ratio of the products.",[28,66],"Viral Sore Throat","RECRUITING","2026-08-03",{"date":70,"type":44},"2026-08-05",{"date":72,"type":44},"2026-07-29",{"date":74,"type":22},"2028-01",{"name":76,"class":51},"University Hospital, Clermont-Ferrand",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100587741","phase-2-qinqiao-yan-shu-granules-for-the-treatment-of-acute-pharyngitis-exterior-wind-heat-syndrome-phase-ii-clinical-trial-100587741","NCT06932328","Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial","A Randomized, Double-Blind, Dose-Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Qin Qiao Yan Shu Granules in the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome)","Inclusion Criteria:\n\n1. Meeting the Western medicine diagnostic criteria for acute pharyngitis.\n2. Meeting the TCM syndrome differentiation criteria for the syndrome of wind-heat invading the exterior.\n3. The disease course at the time of visit is ≤ 48 hours.\n4. The VAS score for pharyngeal pain is ≥ 4 points, and the pharyngeal sign score is ≥ 1 point.\n5. Age between 18 and 65 years old (including the boundary values), regardless of gender.\n6. Voluntarily participating in this clinical trial and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Those with pharyngeal symptoms or inflammation caused by measles, scarlet fever, agranulocytosis, infectious mononucleosis, influenza, diphtheria, acute epiglottitis, acute carotid arteritis, etc.\n2. Those with concurrent acute sinusitis, acute laryngitis, suppurative tonsillitis, bronchitis, pneumonia.\n3. Those with a modified Centor score ≥ 2 points, a peak body temperature \\> 38.5°C (axillary temperature) within 24 hours before this visit, a white blood cell count \\> 1.2 × ULN, a neutrophil percentage \\> 1.2 × ULN, and suspected bacterial infection considered by the researcher.\n4. Those with concurrent severe primary diseases of the cardiovascular and cerebrovascular system, liver, kidney, hematopoietic system, endocrine system, and mental diseases.\n5. Those with a history of thyroid-related diseases such as hyperthyroidism or hypothyroidism.\n6. Those with laboratory test results indicating ALT \\> 1.2 × ULN, AST \\> 1.2 × ULN, or Cr \\> 1 × ULN. Any one of these conditions will lead to exclusion.\n7. Those who have used any other drugs for the treatment of acute pharyngitis, including drugs for relieving pharyngeal pain (such as traditional Chinese medicines, glucocorticoids, non-steroidal anti-inflammatory drugs, etc.) within 48 hours before this visit.\n8. Those who are allergic to the ingredients or excipients of the test drug.\n9. Pregnant or lactating women.\n10. Those suspected of or with a confirmed history of alcohol or drug abuse.\n11. Patients who have participated in or are currently participating in other clinical trials within the past month.\n12. Patients considered by the researcher to be unsuitable for participating in this clinical trial.",{"count":86,"type":22},216,[88],"PHASE2","Trial Objectives and Exploration Indicators：\n\n1. To explore the improvement effect of different doses of Qinqiao Yanshu Granules on the symptoms\u002Fconditions and TCM syndromes of acute pharyngitis (Wind - Heat Exogenous Syndrome), and its effect on shortening the course of the disease.\n2. To observe the safety of the clinical application of Qinqiao Yanshu Granules. Overall Trial Design：A block - randomized, double - blind, dose - escalation, multicenter clinical trial design was adopted.\n\nSample Size：It is planned to enroll 72 cases in each group (high - dose group, low - dose group, and extremely low - dose group), with a total of 216 cases.\n\nInvestigational Products：Experimental groups:\n\n1. High - dose group: Specification: 12g\u002Fbag;\n2. Low - dose group: Specification: 12g\u002Fbag.\n\nControl group:\n\n(1) Extremely low - dose group: Specification: 12g\u002Fbag.\n\nRescue medication:\n\n(1) Paracetamol tablets: Specification: 0.5g\u002Ftablet. Dosage and Administration： High - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Extremely low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Rescue medication: Paracetamol tablets. During the trial, if the subject's body temperature exceeds 38.5°C (including 38.5°C), rescue medication can be added. Use it according to the instructions and doctor's advice and record it truthfully.\n\nTreatment Course：5 days Efficacy Indicators：\n\n1\\) The disappearance rate of pharyngeal pain 3 days and 5 days after treatment; 2) The change value of the pharyngeal pain VAS score compared with the baseline 5 days after treatment; 3) The time to disappearance of pharyngeal pain; 4) The effective rate of pharyngeal signs 5 days after treatment; 5) The clinical cure rate of the disease 5 days after treatment; 6) The efficacy of TCM syndromes 5 days after treatment; 7) The disappearance rate of single symptoms 5 days after treatment; 8) The frequency of rescue drug use. Measurement and Definition of Endpoint Indicators：\n\n1. The criterion for the disappearance of pharyngeal pain: The pharyngeal pain VAS score drops to 0 points and persists for 24 hours or more.\n2. Pharyngeal pain VAS score:\n\n   Starting from the evaluation time of the VAS score during the screening period, the subject evaluates once every 24 hours (±1 hour) and records the most severe degree of pharyngeal pain in the past 24 hours in the diary card.\n3. The criterion for the effective rate of pharyngeal signs: \"Effective\" is defined as a decrease of at least 1 point in the pharyngeal sign score. The effective rate = (Number of effective cases \u002F Total number of cases) × 100%.\n4. The criterion for the clinical cure of the disease: The clinical symptoms of the disease disappear, and the pharyngeal signs are reduced to mild or less. The cure rate = (Number of cured cases \u002F Total number of cases) × 100%.\n5. The definition of the efficacy of TCM syndromes:\n\nEfficacy of TCM syndromes: Cure means that the TCM syndrome score decreases by ≥ 95%; Marked effect means that the TCM syndrome score decreases by ≥ 70% and \\\u003C 95%; Effective means that the TCM syndrome score decreases by ≥ 30% and \\\u003C 70%; Ineffective means that it does not meet the above criteria.\n\nThe change value of the pharyngeal pain VAS score compared with the baseline = The baseline pharyngeal pain VAS score - The pharyngeal pain VAS score on the 6th day.\n\nStudy Population；\n\nInclusion criteria:\n\n1. Meeting the Western medical diagnostic criteria for acute pharyngitis;\n2. Meeting the TCM syndrome differentiation criteria for Wind - Heat Exogenous Syndrome;\n3. The course of the disease at the time of consultation ≤ 48 hours;\n4. The pharyngeal pain VAS score ≥ 4 points and the pharyngeal sign score ≥ 1 point;\n5. Aged between 18 and 65 years old (including the boundary values), regardless of gender;\n6. Voluntarily participating in this clinical trial and signing the informed consent form.\n\nExclusion criteria:\n\n1. Those with pharyngeal symptoms or inflammation caused by measles, scarlet fever, agranulocytosis, infectious mononucleosis, influenza, diphtheria, acute epiglottitis, acute carotid arteritis, etc.;\n2. Those with concurrent acute sinusitis, acute laryngitis, suppurative tonsillitis, bronchitis, pneumonia;\n3. Those with a modified Centor score ≥ 2, a body temperature peak \\> 38.5°C (axillary temperature) within 24 hours before this visit, a white blood cell count \\> 1.2 × ULN, a neutrophil percentage \\> 1.2 × ULN, and considered to be bacterial infections by the researcher;\n4. Those with concurrent severe primary diseases of the cardiovascular and cerebrovascular system, liver, kidney, hematopoietic system, endocrine system, and mental diseases;\n5. Those with a history of thyroid - related diseases such as hyperthyroidism and hypothyroidism;\n6. Those with laboratory test results",[28],"2025-04-10",{"date":93,"type":44},"2025-04-17",{"date":95,"type":44},"2025-03-26",{"date":97,"type":22},"2025-12-31",{"name":99,"class":100},"Jianmin Pharmaceutical Group Co., LTD.","INDUSTRY",7]